Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 2 Interventional Results available

Regimen Optimization Study

ClinicalTrials.gov ID: NCT02137239

Public ClinicalTrials.gov record NCT02137239. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Jul 22, 2026, 7:29 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Evaluation of Acute Rejection Rates in de Novo Renal Transplant Recipients Following Thymoglobulin Induction, CNI-free, Nulojix (Belatacept)-Based Immunosuppression

Study identification

NCT ID
NCT02137239
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2
Lead sponsor
Bristol-Myers Squibb
Industry
Enrollment
58 participants

Conditions and interventions

Interventions

  • Thymoglobulin Drug
  • Belatacept Drug
  • mycophenolate mofetil(MMF) Drug
  • Corticosteroids Drug
  • Everolimus(EVL) Drug
  • Tacrolimus(TAC) Drug

Drug

Eligibility (public fields only)

Age range
18 Years to 75 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Dec 30, 2015
Primary completion
May 1, 2019
Completion
May 1, 2019
Last update posted
Jun 21, 2021

2015 – 2019

United States locations

U.S. sites
17
U.S. states
15
U.S. cities
17
Facility City State ZIP Site status
California Institute Of Renal Research San Diego California 92123
California Pacific Medical Center San Francisco California 94115
University Of Colorado Aurora Colorado 80045
Yale University New Haven Connecticut 06519
MedStar Georgetown University Hospital Washington D.C. District of Columbia 20007
Emory Univeristy Atlanta Georgia 30322
University Of Illinois Chicago Illinois 60612
Tulane Medical Center New Orleans Louisiana 70112
Massachusetts General Hospital Boston Massachusetts 02114
Saint Barnabas Medical Center Livingston New Jersey 07039
Erie County Medical Center Buffalo New York 14215
Wake Forest University School Of Medicine Winston-Salem North Carolina 27157
Central PA Transplant Foundation Harrisburg Pennsylvania 17104
Vanderbilt University Medical Center Nashville Tennessee 37232
University of Virginia Charlottesville Virginia 22908-0709
Inova Fairfax Hospital Falls Church Virginia 22042
Swedish Medical Center - Swedish Colon and Rectal Clinic - First Hill (Northwest Colon and Rectal Cl Seattle Washington 98104

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 3 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT02137239, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jun 21, 2021 · Synced Jul 22, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT02137239 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →